ICU Medical (NASDAQ:ICUI) Lowered to “Hold” Rating by Zacks Research

Zacks Research cut shares of ICU Medical (NASDAQ:ICUI) from a strong-buy rating to a hold rating in a report released on Tuesday,Zacks.com reports.

ICUI has been the subject of several other research reports. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. BTIG Research assumed coverage on shares of ICU Medical in a research report on Monday, June 15th. They set a “buy” rating and a $170.00 price objective for the company. Finally, Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $172.00.

ICU Medical Trading Up 0.5%

NASDAQ:ICUI opened at $166.53 on Tuesday. The company has a quick ratio of 1.17, a current ratio of 2.34 and a debt-to-equity ratio of 0.60. The business’s 50 day moving average is $146.57 and its two-hundred day moving average is $140.00. ICU Medical has a 52 week low of $107.00 and a 52 week high of $170.48. The company has a market cap of $4.16 billion, a PE ratio of 90.02, a P/E/G ratio of 2.32 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The business’s quarterly revenue was down 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts predict that ICU Medical will post 6.51 EPS for the current year.

Insiders Place Their Bets

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of ICU Medical

Large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after purchasing an additional 89,755 shares during the period. Janus Henderson Group PLC increased its stake in shares of ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock valued at $345,607,000 after purchasing an additional 99,256 shares during the period. Millennium Management LLC raised its holdings in shares of ICU Medical by 173.4% during the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after buying an additional 690,694 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of ICU Medical by 6.8% during the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock valued at $127,053,000 after buying an additional 63,026 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of ICU Medical by 2.8% during the fourth quarter. State Street Corp now owns 942,670 shares of the medical instruments supplier’s stock valued at $134,491,000 after buying an additional 25,545 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.